血浆纤溶抑制物与2型糖尿病患者凝血及纤溶功能变化的关系  

Relationship between thrombin activated fibrinolysis inhibitor in plasma and changes of coagulant and fibrinolytic function in type 2 diabetes

作　　者：钟兰君[1] 李晓娜[2] 丁进芳[1] 王凤兰[1] 李芳文[1] 张兴旺[1] 

机构地区：[1]甘肃省人民医院临床检验中心,兰州730000 [2]兰州大学2003级

出　　处：《国际检验医学杂志》2006年第5期401-402,共2页International Journal of Laboratory Medicine

摘　　要：目的评价血浆纤溶抑制物(TAFI)与2型糖尿病患者凝血及纤溶功能变化的关系。方法血浆TAFI水平采用ELISA测定,纤维蛋白原(Fib)采用凝血酶法测定,纤溶酶原(PLG)活性通过发色底物法检测。结果与正常对照组比较,2型糖尿病无并发症组血浆TAFI、Fib水平及PLG活性均升高,差异有统计学意义(P<0.05);而2型糖尿病血管并发症组血浆TAFI、Fib水平及PLG活性升高更显著,差异有统计学意义(P<0.001);同时,2型糖尿病患者血浆TAFI与Fib水平及PLG活性显著相关(P<0.05)。结论2型糖尿病凝血及纤溶功能的变化与血浆TAFI水平的升高有关。Objective To evaluate the relationship of thrombin activated fibrinolysis inhibitor （TAFI） in plasma with changes of coagulant and fibrinolytic function in type 2 diabetes. Methods The plasma level of TAFI was measured by ELISA, fibrinogen was analyzed with Clauss assay and plasminogen was detected by chromogenic assay. Results The plasma levels of TAFI, Fib and the activity of PLG were significantly increased in type 2 diabetes with （P〈0.001）or without any complication （P〈0.05） than normal subjects. The plasma levels of TAFI were positively correlated with the plasma level of Fib and the activity of PLG in type 2 diabetes. Conclusion The increased plasma level of TAFI may be involved in the mechanism of changes of coagulant and fibrinolytic function in type 2 diabetes.

关 键 词：纤溶酶原灭活剂 糖尿病 2型 血液凝固 纤维蛋白溶解 

分 类 号：R587.1[医药卫生—内分泌] R446.112[医药卫生—内科学]